NOVI Health's Hybrid Care Model Achieves Clinical Trial-Level Weight Loss in Real-World GLP-1 Treatment
核心洞察
A new study published in the International Journal of Obesity demonstrates that NOVI Health (搜索)'s hybrid care model achieved 14.7% weight loss at 18 months in a multi-ethnic Asian population, matching clinical trial results.
The study of 708 adults showed that combining GLP-1 medications with digital coaching significantly outperformed typical real-world GLP-1 outcomes, which usually fall short at around 9% weight loss at 12 months.
Participants who actively engaged with NOVI's digital platform achieved 2.0-2.2 percentage points of additional weight loss compared to low engagers, demonstrating the measurable impact of behavioral support.
A groundbreaking study has demonstrated that integrating digital coaching with GLP-1 medications can bridge the significant gap between clinical trial outcomes and real-world treatment results for obesity. The research, published in the International Journal of Obesity, shows that NOVI Health (搜索)'s hybrid care model achieved weight loss results comparable to landmark clinical trials in a diverse Asian population.
The study, conducted in collaboration with the Saw Swee Hock School of Public Health at the National University of Singapore, evaluated 708 adults enrolled in NOVI Optimum Plus, a physician-led obesity care program. Participants achieved an estimated 12.7% mean weight loss at 12 months and 14.7% at 18 months, significantly exceeding typical real-world GLP-1 outcomes of around 9% at 12 months.
Addressing the Real-World Treatment Gap
GLP-1 medications have transformed obesity treatment, but real-world results consistently fall short of clinical trial outcomes. While landmark trials like STEP 1 reported 15% weight loss, real-world applications typically achieve only 9% at 12 months due to high discontinuation rates, suboptimal dosing, and lack of structured behavioral support.
The NOVI study demonstrates that combining GLP-1 receptor agonist medications with app-based digital coaching and personalized lifestyle support can effectively close this performance gap. The results represent one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population.
Digital Engagement Drives Superior Outcomes
The research revealed that medication alone is insufficient for optimal results. Participants who actively engaged with NOVI's digital platform achieved meaningfully better outcomes compared to low engagers:
- 2.0 to 2.2 percentage points of additional weight loss, equivalent to roughly 15% greater relative weight loss
- Approximately 0.72 kg/m² greater BMI reduction
- Up to 2.9 mmHg additional systolic blood pressure reduction
These findings demonstrate that digital coaching acts as a measurable multiplier for GLP-1 treatment effectiveness.
Ethnic Variation Highlights Need for Personalized Care
The study's multi-ethnic cohort revealed significant variation in treatment response across different populations. The participant breakdown included approximately 45% East Asian, 27% European, 13% South Asian, and 10% Southeast Asian individuals.
East Asian participants and individuals with hyperglycemia experienced comparatively lower weight loss, while European and mixed-ethnicity participants achieved greater reductions. This variation underscores the importance of tailored treatment approaches.
"A one-size-fits-all approach to GLP-1 prescribing does not work in Asia," said Dr. Sue-Anne Toh, co-founder and Medical Director of NOVI Health (搜索), Adjunct Associate Professor at NUS Yong Loo Lin School of Medicine, and the study's senior author. "Different metabolic profiles and ethnic backgrounds demand a tailored approach. That is exactly what our hybrid model is designed to deliver."
Clinical Implications
The study's findings have significant implications for obesity treatment protocols, particularly in diverse populations. By demonstrating that structured behavioral support can help real-world outcomes match clinical trial results, the research provides evidence for integrating digital health solutions into standard GLP-1 treatment protocols.
The results suggest that healthcare providers should consider comprehensive care models that combine pharmacological interventions with sustained behavioral support to optimize patient outcomes and address the current treatment efficacy gap in real-world settings.